|
|
Request Number: 5.8
The Office of Technology Management is in contact with a company who is looking to in- license-exclusive or non-exclusive monoclonal or polyclonal antibodies specific for the following targets:
- Apo-E2 - Protein implied in the evolution of Alzheimer's Disease
- Apo-E3 - Protein implied in the evolution of Alzheimer's Disease
- Apo-E4 - Protein implied in the evolution of Alzheimer's Disease
- Aph-1 - Protein implied in the evolution of Alzheimer's Disease
- Notch - Protein implied in the evolution of Alzheimer's Disease
- Presenilin-1 - Protein implied in the evolution of Alzheimer's Disease
- Presenilin-2 - Protein implied in the evolution of Alzheimer's Disease
- Park-8 - Protein implied in the evolution of Parkinson's Disease
- Pink-1 - Protein implied in the evolution of Parkinson's Disease
- Bace 1,Bace 2 - Protein implied in the evolution of Alzheimer's Disease
- Pen-2 - Protein implied in the evolution of Alzheimer's Disease
- Bag5 - Protein implied in the Parkinson's Disease
- sAPPbeta - Protein implied in the Alzheimer's Disease
Neurodegenerative Diseases
- Apo-E2,E3,E4 - Proteins implicated in the pathogenesis of Alzheimer's Disease
- Beta Amyloid - Protein implicated in the pathogenesis of Alzheimer's Disease
- Beta Synuclein - Protein implicated in the pathogenesis of Parkinson's Disease
- Gamma Synuclein - Protein implicated in the pathogenesis of Parkinson's Disease
- RHO Kinases - Proteins implied in signal transduction
Renal Diseases
- pi-GST -(Glutathione S-Transferase) Protein implied in renal cell injury
- alpha-GST - (Glutathione S-Transferase) Protein implied in renal cell injury
- NGAL - Protein implied in renal cell injury
Please contact the Office of Technology Management if you have any technology that may be relevant to this request. |